<p>Immatics（納斯達克股票代碼：IMTX - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場開盤前發佈其 2026 年第一季度財報。分析師預計該公司將宣佈每股收益為（$0.42）以及該季度收入為 979.30 萬美元。各方被鼓勵查看該公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 13 日東部時間下午 12:30 的電話會議的最新信息。</p>
<p>Immatics（納斯達克股票代碼：IMTX - 獲取免費報告）上一次發佈季度財報是在 3 月 5 日星期四。該公司報告的季度每股收益為（$0.34），超出分析師一致預期的（$0.48）$0.14。該季度公司的收入為 2318 萬美元，而一致預期為 1218 萬美元。Immatics 的淨利潤率為-411.90%，股本回報率為-41.81%。分析師平均預計 Immatics 在當前財政年度的每股收益為-$1，下一財政年度的每股收益也為-$1。</p>
<h2>Immatics 股票表現</h2>
<p>在週二的午盤交易中，納斯達克股票代碼：IMTX 的股價下跌了$0.22，達到$10.93。該公司 219,242 股股票被交易，較其平均交易量 426,446 股有所減少。該公司的 50 日簡單移動平均為$10.29，200 日簡單移動平均為$10.11。該公司的市值為 14.6 億美元，市盈率為-5.94，貝塔值為 1.31。Immatics 的 12 個月低點為$3.94，12 個月高點為$12.41。</p>
<h2>機構投資者對 Immatics 的看法</h2>
<p>幾家大型投資者最近對該公司的持倉進行了調整。T. Rowe Price Investment Management Inc.在第四季度將其在 Immatics 的持股增加了 10.7%。T. Rowe Price Investment Management Inc.目前擁有 21,459,156 股該公司的股票，價值 225,322,000 美元，此前在上個季度購買了 2,075,987 股。Virtus Investment Advisers LLC 在第四季度將其在 Immatics 的持股增加了 43.0%。Virtus Investment Advisers LLC 目前擁有 26,497 股該公司的股票，價值 278,000 美元，此前在上個季度增持了 7,965 股。SummitTX Capital L.P.在第四季度將其在 Immatics 的持股增加了 117.7%。SummitTX Capital L.P.目前擁有 96,784 股該公司的股票，價值 1,016,000 美元，此前在上個季度增持了 52,318 股。Tudor Investment Corp ET AL 在第四季度購買了 Immatics 的新股份，價值約 575,000 美元。最後，Sphera Funds Management LTD.在第四季度將其在 Immatics 的持股增加了 47.7%。Sphera Funds Management LTD.目前擁有 861,105 股該公司的股票，價值 9,042,000 美元，此前在上個季度增持了 278,000 股。機構投資者持有該公司 64.41% 的股份。</p>
<h2>華爾街分析師預測增長</h2>
<p>IMTX 成為多份分析師報告的主題。Wall Street Zen 在週六將 Immatics 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 1 月 22 日星期四重申了對 Immatics 股票的 “賣出（d-）” 評級。TD Cowen 在 4 月 28 日星期二開始對 Immatics 的股票進行覆蓋，並給予該股票 “買入” 評級。Jefferies Financial Group 在 3 月 16 日星期一開始對 Immatics 的股票進行覆蓋，並給予該股票 “買入” 評級和$18.00 的目標價。最後，瑞穗證券在 2 月 19 日星期四對 Immatics 的股票設定了$25.00 的目標價。七位研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，Immatics 的平均評級為 “適度買入”，共識目標價為$19.00。</p>
<p><strong>查看我們對 IMTX 的最新分析</strong></p>
<h2>Immatics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immatics N.V. 納斯達克：IMTX 是一家臨牀階段的生物技術公司，致力於開發基於 T 細胞受體（TCR）的免疫療法用於實體瘤。該公司利用其專有的發現和工程平台來識別腫瘤特異性肽靶點，並開發利用患者免疫系統力量的療法。Immatics 的方法旨在通過引導 T 細胞識別並精準殺死癌細胞來產生持久的反應。</p>
<p>Immatics 技術套件的核心是 XPRESIDENT®平台，該平台挖掘癌症肽組，以發現自然呈現在癌細胞表面的新型腫瘤抗原。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Immatics 更具吸引力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Immatics 嗎？</h2>
<p>在你考慮 Immatics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Immatics 並不在名單上。</p>
<p>雖然 Immatics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMTX

<p>Immatics（納斯達克股票代碼：IMTX）將於 5 月 12 日發佈 2026 年第一季度財報，分析師預測每股虧損 0.42 美元，收入為 979 萬美元。該公司在 2025 年第四季度報告的每股虧損為 0.34 美元，收入為 2318 萬美元。機構投資者持有該股票的 64.41%。最近的分析師評級包括七個 “買入” 和一個 “賣出”。該股票目前交易價格為 10.93 美元，市值為 14.6 億美元，市場共識目標價為 19.00 美元</p>

<p>Immatics (NASDAQ:IMTX - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $9.7930 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 12:30 PM ET.</p>
<div class="lb-trans"><p>Immatics（納斯達克股票代碼：IMTX - 獲取免費報告）預計將在 2026 年 5 月 12 日星期二市場開盤前發佈其 2026 年第一季度財報。分析師預計該公司將宣佈每股收益為（$0.42）以及該季度收入為 979.30 萬美元。各方被鼓勵查看該公司即將發佈的 2026 年第一季度財報概覽頁面，以獲取關於定於 2026 年 5 月 13 日東部時間下午 12:30 的電話會議的最新信息。</p>
</div><p>Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.14. The company had revenue of $23.18 million during the quarter, compared to the consensus estimate of $12.18 million. Immatics had a negative net margin of 411.90% and a negative return on equity of 41.81%. On average, analysts expect Immatics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Immatics（納斯達克股票代碼：IMTX - 獲取免費報告）上一次發佈季度財報是在 3 月 5 日星期四。該公司報告的季度每股收益為（$0.34），超出分析師一致預期的（$0.48）$0.14。該季度公司的收入為 2318 萬美元，而一致預期為 1218 萬美元。Immatics 的淨利潤率為-411.90%，股本回報率為-41.81%。分析師平均預計 Immatics 在當前財政年度的每股收益為-$1，下一財政年度的每股收益也為-$1。</p>
</div><h2>Immatics Stock Performance</h2>
<div class="lb-trans"><h2>Immatics 股票表現</h2>
</div><p>Shares of NASDAQ:IMTX traded down $0.22 during midday trading on Tuesday, reaching $10.93. 219,242 shares of the company's stock were exchanged, compared to its average volume of 426,446. The company's 50 day simple moving average is $10.29 and its two-hundred day simple moving average is $10.11. The firm has a market capitalization of $1.46 billion, a PE ratio of -5.94 and a beta of 1.31. Immatics has a 12 month low of $3.94 and a 12 month high of $12.41.</p>
<div class="lb-trans"><p>在週二的午盤交易中，納斯達克股票代碼：IMTX 的股價下跌了$0.22，達到$10.93。該公司 219,242 股股票被交易，較其平均交易量 426,446 股有所減少。該公司的 50 日簡單移動平均為$10.29，200 日簡單移動平均為$10.11。該公司的市值為 14.6 億美元，市盈率為-5.94，貝塔值為 1.31。Immatics 的 12 個月低點為$3.94，12 個月高點為$12.41。</p>
</div><h2>Institutional Investors Weigh In On Immatics</h2>
<div class="lb-trans"><h2>機構投資者對 Immatics 的看法</h2>
</div><p>Several large investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its holdings in shares of Immatics by 10.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company's stock worth $225,322,000 after purchasing an additional 2,075,987 shares during the last quarter. Virtus Investment Advisers LLC grew its holdings in Immatics by 43.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 26,497 shares of the company's stock worth $278,000 after acquiring an additional 7,965 shares during the last quarter. SummitTX Capital L.P. grew its holdings in Immatics by 117.7% during the 4th quarter. SummitTX Capital L.P. now owns 96,784 shares of the company's stock worth $1,016,000 after acquiring an additional 52,318 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in Immatics during the 4th quarter worth about $575,000. Finally, Sphera Funds Management LTD. grew its holdings in Immatics by 47.7% during the 4th quarter. Sphera Funds Management LTD. now owns 861,105 shares of the company's stock worth $9,042,000 after acquiring an additional 278,000 shares during the last quarter. Institutional investors own 64.41% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近對該公司的持倉進行了調整。T. Rowe Price Investment Management Inc.在第四季度將其在 Immatics 的持股增加了 10.7%。T. Rowe Price Investment Management Inc.目前擁有 21,459,156 股該公司的股票，價值 225,322,000 美元，此前在上個季度購買了 2,075,987 股。Virtus Investment Advisers LLC 在第四季度將其在 Immatics 的持股增加了 43.0%。Virtus Investment Advisers LLC 目前擁有 26,497 股該公司的股票，價值 278,000 美元，此前在上個季度增持了 7,965 股。SummitTX Capital L.P.在第四季度將其在 Immatics 的持股增加了 117.7%。SummitTX Capital L.P.目前擁有 96,784 股該公司的股票，價值 1,016,000 美元，此前在上個季度增持了 52,318 股。Tudor Investment Corp ET AL 在第四季度購買了 Immatics 的新股份，價值約 575,000 美元。最後，Sphera Funds Management LTD.在第四季度將其在 Immatics 的持股增加了 47.7%。Sphera Funds Management LTD.目前擁有 861,105 股該公司的股票，價值 9,042,000 美元，此前在上個季度增持了 278,000 股。機構投資者持有該公司 64.41% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>IMTX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Immatics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Immatics in a report on Thursday, January 22nd. TD Cowen began coverage on shares of Immatics in a report on Tuesday, April 28th. They issued a &#34;buy&#34; rating on the stock. Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $18.00 target price on the stock. Finally, Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Immatics has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $19.00.</p>
<div class="lb-trans"><p>IMTX 成為多份分析師報告的主題。Wall Street Zen 在週六將 Immatics 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 1 月 22 日星期四重申了對 Immatics 股票的 “賣出（d-）” 評級。TD Cowen 在 4 月 28 日星期二開始對 Immatics 的股票進行覆蓋，並給予該股票 “買入” 評級。Jefferies Financial Group 在 3 月 16 日星期一開始對 Immatics 的股票進行覆蓋，並給予該股票 “買入” 評級和$18.00 的目標價。最後，瑞穗證券在 2 月 19 日星期四對 Immatics 的股票設定了$25.00 的目標價。七位研究分析師對該股票給予了 “買入” 評級，一位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，Immatics 的平均評級為 “適度買入”，共識目標價為$19.00。</p>
</div><p><strong>View Our Latest Analysis on IMTX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 IMTX 的最新分析</strong></p>
</div><h2>Immatics Company Profile</h2>
<div class="lb-trans"><h2>Immatics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immatics N.V. NASDAQ: IMTX is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient's immune system. Immatics' approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.</p>
<div class="lb-trans"><p>Immatics N.V. 納斯達克：IMTX 是一家臨牀階段的生物技術公司，致力於開發基於 T 細胞受體（TCR）的免疫療法用於實體瘤。該公司利用其專有的發現和工程平台來識別腫瘤特異性肽靶點，並開發利用患者免疫系統力量的療法。Immatics 的方法旨在通過引導 T 細胞識別並精準殺死癌細胞來產生持久的反應。</p>
</div><p>At the core of Immatics' technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.</p>
<div class="lb-trans"><p>Immatics 技術套件的核心是 XPRESIDENT®平台，該平台挖掘癌症肽組，以發現自然呈現在癌細胞表面的新型腫瘤抗原。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Immatics</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Immatics 更具吸引力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU1UWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IMTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immatics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Immatics 嗎？</h2>
</div><p>Before you consider Immatics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Immatics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Immatics 並不在名單上。</p>
</div><p>While Immatics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immatics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immatics (IMTX) 將在週二公佈季度收益